This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Oncology  • Breast Cancer  • Women's Health  • Women's Health, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Breast carcinoma in situ (BCIS) comprises 20% of new breast cancer diagnoses, with 2 predominant histologic forms: ductal (DCIS) and lobular (LCIS).¹ Women with DCIS often undergo treatment similar to that of women with localized invasive cancer and experience similar reductions in quality of life.² Women diagnosed with either DCIS or LCIS are approximately 4 times more likely to develop invasive breast cancer compared with the general population.³ The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute reports that there were 2.5 million survivors of invasive breast cancer alive in the United States in 2005,¹ but we are aware of no published estimates of BCIS prevalence.

Methods

The prevalence of BCIS on January 1, 2005, was estimated by applying age- and race-specific prevalence proportions from the SEER 9 registries to the US population.⁴ Individual SEER registries determined and reported race classifications. The counting method . . . [Full Text of this Article]

Brian L. Sprague, MS
bsprague@wisc.edu

Amy Trentham-Dietz, PhD
Department of Population Health Sciences
University of Wisconsin-Madison

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?